

Mechanism of imipenem Resistance in *Acinetobacter baumannii* Isolates from a Regional Hospital in Taiwan

陳書虹、劉淑瑛 邱政洵

E-mail: 9901216@mail.dyu.edu.tw

ABSTRACT

Acinetobacter baumannii is an opportunistic pathogen causing nosocomial infections in immunocompromised and elderly patients. Imipenem is antibiotic of choice to treat such infections. However, the fast emerging drug-resistant *A. baumannii* poses difficulty in the treatment usage. In order to elucidate the resistance mechanisms, 20 imipenem-resistant *A. baumannii* clinical isolates from a regional hospital in Taiwan were collected and examined in this study. E-test analysis showed all isolates were susceptible to colistin, and twelve isolates were intermediately resistant to tigecycline. All isolates were resistant to imipenem, ciprofloxacin, and ceftazidime. PCR amplification and sequence analysis identified blaOXA-23, bla OXA-66 and blaADC-25 in these isolates. The upstream ISAb1 contributing to its downstream gene expression, is always found in blaOXA-23 and blaADC-25, and in blaOXA-66 of three isolates. Further sequence analysis showed that blaOXA-23 was carried by transposon Tn2006. The imipenem resistance in the isolates of *A. baumannii* was likely due to the expression of either blaOXA-23 or blaOXA-66. We concluded that imipenem resistance in *A. baumannii* isolates from the regional hospital was likely due to the hyper-expression of OXA-type -lactamases. Colistin still remained active in vitro (MIC 0.38 - 0.75 μg / ml).

Keywords : *Acinetobacter baumannii*, imipenem, -lactamases, blaOXA-23, blaOXA-66, blaADC-25, ISAb1

Table of Contents

授權書.....	iii 中文摘要.....	iv 英文摘要.....
要.....	.vi 誌謝.....	vii 目.....
錄.....	ix 圖目錄.....	xii 表目.....
錄.....	xiii 1. 緒論.....	1 1.1 不動桿菌 (<i>Acinetobacter</i>).....
制.....	1 1.2 鮑氏不動桿菌 (<i>Acinetobacter baumannii</i>).....	1 1.3 抗生素作用機.....
制.....	2 1.4 細菌抗藥機制.....	4 1.5 鮑氏不動桿菌的抗藥機.....
響.....	5 1.6 -lactamase.....	6 1.7 ISAb1 對於抗藥性的影.....
法.....	7 1.8 研究動機.....	8 2. 材料與方.....
性測試.....	9 2.1 菌株來源與保存.....	9 2.2 菌株最小抑菌濃度與抗藥.....
(PCR)	9 - ix - 2.3 Metallo- -Lactamase 測試.....	10 2.4 Polymerase chain reaction.....
定.....	10 2.4.1 PCR 模板 DNA 製備.....	10 2.4.2 引子設計與條件設.....
計.....	10 2.5 Real-time polymerase chain reaction (Real-time PCR)	11 2.5.1 引子設.....
作.....	11 2.5.2 cDNA 製備.....	12 2.5.3 Real-time PCR 操.....
備.....	12 2.6 南方墨點法 (Southern hybridization)	13 2.6.1 探針製.....
型.....	13 2.6.2 plasmid 抽取.....	13 2.6.3 毛細轉瀆法 (Capillary transfer)
果.....	14 2.6.4 雜合反應與顯影.....	14 2.7 基因分.....
試.....	14 3. 實驗結果.....	16 3.1 菌株最小抑菌濃度測試結.....
(Southern hybridization) 測試結果.....	16 3.2 Metallo- -lactamase 反應測試結果.....	16 3.3 -Lactamase抗藥基因測.....
論.....	17 3.4 blaOXA-23與blaOXA-66基因表現量測試.....	17 3.5 南方墨點法.....
4.6 imipenem 抗藥性菌株基因分型.....	18 3.6 IRS-PCR 分型結果.....	19 4. 結果討.....
獻.....	20 4.1 菌株抗藥性.....	20 4.2 Metallo- -Lactamase.....
	21 4.3 基因 blaOXA-23、blaOXA-66 與 blaADC-25	21 4.4.....
	blaOXA-23 與 blaOXA-66 基因位置.....	22 4.5 blaOXA-23 與 blaOXA-66 基因表現.....
	24 5. 結論.....	23.....
	44	25 參考文.....

REFERENCES

1. Ambler, R. P. 1980. The structure of beta-lactamases. *Philos.Trans.R.Soc.Lond B Biol.Sci.* 289:321-331. 2. Arakawa, Y., N. Shibata, K. Shibayama, H. Kurokawa, T. Yagi, H. Fujiwara, and M. Goto. 2000. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. *J.Clin.Microbiol.* 38:40-43. 3. Bertini, A., L. Poirel, S. Bernabeu, D. Fortini, L. Villa, P. Nordmann, and A. Carattoli. 2007. Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 51:2324-2328. 4. Brown, S. and S. Amyes. 2006. OXA (beta)-lactamases in *Acinetobacter*: the story so far. *J.Antimicrob.Chemother.* 57:1-3. 5. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob.Agents Chemother.* 39:1211-1233. 6. Chen, C. M., P. Y. Liu, S. C. Ke, H. J. Wu, and L. T. Wu. 2009. Investigation of carbapenem-resistant *Acinetobacter baumannii* isolates in a district hospital in Taiwan. *Diagn.Microbiol.Infect.Dis.* 63:394-397. 7. Chen, T. L., R. C. Wu, M. F. Shaio, C. P. Fung, and W. L. Cho. 2008. Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 52:2573-2580. 8. Corvec, S., N. Caroff, E. Espaze, C. Giraudeau, H. Drugeon, and A. Reynaud. 2003. AmpC cephalosporinase hyperproduction in *Acinetobacter baumannii* clinical strains. *J.Antimicrob.Chemother.* 52:629-635. 9. Corvec, S., L. Poirel, T. Naas, H. Drugeon, and P. Nordmann. 2007. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene bla in OXA-23 - 44 - *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 51:1530-1533. 10. Dijkshoorn, L., A. Nemec, and H. Seifert. 2007. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat.Rev.Microbiol.* 5:939-951. 11. Dorsey, C. W., A. P. Tomaras, and L. A. Actis. 2002. Genetic and phenotypic analysis of *Acinetobacter baumannii* insertion derivatives generated with a transposome system. *Appl.Environ.Microbiol.* 68:6353-6360. 12. Figueiredo, S., L. Poirel, J. Croize, C. Recule, and P. Nordmann. 2009. In vivo selection of reduced susceptibility to carbapenems in *Acinetobacter baumannii* related to ISAbal-mediated overexpression of the natural bla(OXA-66) oxacillinase gene. *Antimicrob.Agents Chemother.* 53:2657-2659. 13. Fischbach, M. A. and C. T. Walsh. 2009. Antibiotics for emerging pathogens. *Science* 325:1089-1093. 14. Heritier, C., L. Poirel, and P. Nordmann. 2006. Cephalosporinase over-expression resulting from insertion of ISAbal in *Acinetobacter baumannii*. *Clin.Microbiol.Infect.* 12:123-130. 15. Hu, W. S., S. M. Yao, C. P. Fung, Y. P. Hsieh, C. P. Liu, and J. F. Lin. 2007. An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 51:3844-3852. 16. Hujer, K. M., N. S. Hamza, A. M. Hujer, F. Perez, M. S. Helfand, C. R. Bethel, J. M. Thomson, V. E. Anderson, M. Barlow, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2005. Identification of a new allelic variant of the *Acinetobacter baumannii* cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. *Antimicrob.Agents Chemother.* 49:2941-2948. 17. Kado, C. I. and S. T. Liu. 1981. Rapid procedure for detection and isolation of large and small plasmids. *J.Bacteriol.* 145:1365-1373. 18. Karageorgopoulos, D. E., T. Kelesidis, I. Kelesidis, and M. E. Falagas. 2008. Tigecycline for the treatment of multidrug-resistant (including carbapenem- resistant) *Acinetobacter* infections: a review of the scientific evidence. *J.Antimicrob.Chemother.* 62:45-55. 19. Koeleman, J. G., J. Stoof, D. J. Biesmans, P. H. Savelkoul, and C. M. Vandenbroucke-Grauls. 1998. Comparison of amplified ribosomal DNA restriction analysis, random amplified polymorphic DNA analysis, and amplified fragment length polymorphism fingerprinting for identification of *Acinetobacter* genomic species and typing of *Acinetobacter baumannii*. *J.Clin.Microbiol.* 36:2522-2529. 20. Lee, Y. T., L. Y. Huang, D. H. Chiang, C. P. Chen, T. L. Chen, F. D. Wang, C. P. Fung, L. K. Siu, and W. L. Cho. 2009. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible *Acinetobacter* isolates belonging to different genomic species in Taiwan. *Int.J.Antimicrob.Agents* 34:580-584. 21. Loehfelm, T. W., N. R. Luke, and A. A. Campagnari. 2008. Identification and characterization of an *Acinetobacter baumannii* biofilm-associated protein. *J.Bacteriol.* 190:1036-1044. 22. Lu, P. L., M. Doumith, D. M. Livermore, T. P. Chen, and N. Woodford. 2009. Diversity of carbapenem resistance mechanisms in *Acinetobacter baumannii* from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. *J.Antimicrob.Chemother.* 63:641-647. 23. Magnet, S., P. Courvalin, and T. Lambert. 2001. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob.Agents Chemother.* 45:3375-3380. 24. Mak, J. K., M. J. Kim, J. Pham, J. Tapsall, and P. A. White. 2009. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant *Acinetobacter baumannii*. *J.Antimicrob.Chemother.* 63:47-54. 25. Mammeri, H., L. Poirel, N. Mangeney, and P. Nordmann. 2003. Chromosomal integration of a cephalosporinase gene from *Acinetobacter baumannii* into *Oligella urethralis* as a source of acquired resistance to beta-lactams. *Antimicrob.Agents Chemother.* 47:1536-1542. 26. Massova, I. and S. Mobashery. 1998. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. *Antimicrob.Agents Chemother.* 42:1-17. 27. mier-Piolle, L., S. Magnet, S. Bremont, T. Lambert, and P. Courvalin. 2008. AdelJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 52:557-562. 28. Peleg, A. Y., J. Adams, and D. L. Paterson. 2007. Tigecycline Efflux as a Mechanism for Nonsusceptibility in *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 51:2065-2069. 29. Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin.Microbiol.Rev.* 21:538-582. 30. Poirel, L., S. Marque, C. Heritier, C. Segonds, G. Chabanon, and P. Nordmann. 2005. OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 49:202-208. 31. Queenan, A. M. and K. Bush. 2007. Carbapenemases: the versatile beta-lactamases. *Clin.Microbiol.Rev.* 20:440-58, table. 32. Segal, H., R. K. Jacobson, S. Garny, C. M. Bamford, and B. G. Elisha. 2007. Extended -10 promoter in ISAbal upstream of blaOXA-23 from *Acinetobacter baumannii*. *Antimicrob.Agents Chemother.* 51:3040-3041. 33. Segal, H., E. C. Nelson, and B. G. Elisha. 2004. Genetic environment and transcription of ampC in an *Acinetobacter baumannii* clinical isolate. *Antimicrob.Agents Chemother.* 48:612-614. 34. Seward, R. J. and K. J. Towner. 1998. Molecular epidemiology of quinolone resistance in

Acinetobacter spp. Clin.Microbiol.Infect. 4:248-254. 35. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-beta-lactamases: the quiet before the storm? Clin.Microbiol.Rev. 18:306-325. 36. Wu, T. L., L. H. Su, H. S. Leu, C. H. Chiu, Y. P. Chiu, J. H. Chia, A. J. Kuo, and C. F. Sun. 2002. Molecular epidemiology of nosocomial infection associated with multi-resistant *Acinetobacter baumannii* by infrequent-restriction-site PCR. J.Hosp.Infect. 51:27-32. 37. Zarrilli, R., M. Crispino, M. Bagattini, E. Barretta, P. A. Di, M. Triassi, and P. Villari. 2004. Molecular epidemiology of sequential outbreaks of *Acinetobacter baumannii* in an intensive care unit shows the emergence of carbapenem resistance. J.Clin.Microbiol. 42:946-953. 38. Zarrilli, R., D. Vitale, P. A. Di, M. Bagattini, Z. Daoud, A. U. Khan, C. Afif, and M. Triassi. 2008. A plasmid-borne blaOXA-58 gene confers imipenem resistance to *Acinetobacter baumannii* isolates from a Lebanese hospital. Antimicrob.Agents Chemother. 52:4115-4120.